ALBUQUERQUE, N.M.–(BUSINESS WIRE)–Agilvax, Inc., a biotechnology company developing targeted antibody-based therapeutics for the treatment of various types of cancers announced today that Joseph Patti, Ph.D., will join its Board of Directors as Executive Chairman. Dr. Patti has over two decades of drug development experience in the biopharmaceutical industry and has
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported that eight abstracts–including two oral presentations–on the Company’s lead product candidate rivo-cel (formerly BPX-501), in addition to an abstract on its controllable CAR program, were accepted for presentation at the 60th American
Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that two of its commercial partners, Sebacia, Inc. and LiteCure, LLC, have advanced towards commercialization and indicated plans for commercial launch in the United States in 2019.
Four Houston high-achievers earned top honors as the 2019 Women in Science with Excellence (WISE) honorees, BioHouston announced today. The award recognizes women in science-related roles who have made significant contributions in science, technology, engineering or mathematics.
Jim Allison, Ph.D. today was awarded the 2018 Nobel Prize in Physiology or Medicine for launching an effective new way to attack cancer by treating the immune system rather than the tumor.
The Southwest National Pediatric Device Consortium recently received a prestigious P50 grant from the U.S. FDA. Proxima Clinical Research, Inc. is honored to be a part of this consortium.